Thymosin Alpha-1

An immunomodulating peptide from thymus tissue, approved in some countries as thymalfasin for hepatitis and studied in sepsis.

What research shows

Thymosin alpha-1 is among the better studied compounds here: randomized trials cover severe sepsis, chronic hepatitis and adjuvant cancer treatment, and it holds marketing authorisation as thymalfasin in some countries. Evidence quality varies by indication, and it carries no United States authorisation.

Evidence strength

Highest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.